Karin Milde-Langosch Selected Research

Activated-Leukocyte Cell Adhesion Molecule (Neurolin)

11/2019	Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
1/2013	Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells.
4/2012	Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.
1/2012	Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.
9/2011	Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
2/2011	Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karin Milde-Langosch Research Topics

Disease

50	Neoplasms (Cancer) 06/2022 - 02/2002
35	Breast Neoplasms (Breast Cancer) 06/2022 - 02/2002
19	Carcinoma (Carcinomatosis) 01/2018 - 02/2002
15	Neoplasm Metastasis (Metastasis) 06/2022 - 11/2008
14	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 04/2003
7	Ovarian Epithelial Carcinoma 01/2022 - 07/2009
4	Carcinogenesis 10/2014 - 02/2003
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 11/2008
2	Brain Neoplasms (Brain Tumor) 01/2017 - 01/2011
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 04/2012 - 01/2011
1	Residual Neoplasm 01/2022
1	Lymphatic Metastasis 06/2017
1	Ovarian Diseases (Ovarian Disease) 01/2016
1	Triple Negative Breast Neoplasms 12/2014
1	Breast Diseases (Breast Disease) 10/2011
1	Ductal Carcinoma 09/2011
1	Vulvar Neoplasms (Vulvar Cancer) 01/2011

Drug/Important Bio-Agent (IBA)

27	Proteins (Proteins, Gene)FDA Link 08/2021 - 02/2002
19	Messenger RNA (mRNA)IBA 01/2020 - 02/2003
7	Estrogen ReceptorsIBA 08/2021 - 01/2006
7	EnzymesIBA 11/2019 - 01/2011
6	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 11/2019 - 02/2011
5	Cell Adhesion MoleculesIBA 06/2022 - 02/2002
5	Biomarkers (Surrogate Marker)IBA 04/2016 - 11/2008
5	Hormones (Hormone)IBA 10/2014 - 02/2002
5	RNA (Ribonucleic Acid)IBA 06/2014 - 11/2010
5	Transcription Factors (Transcription Factor)IBA 10/2013 - 07/2004
4	Polysaccharides (Glycans)IBA 11/2019 - 06/2014
4	MicroRNAs (MicroRNA)IBA 03/2016 - 08/2012
4	Phenobarbital (Luminal)FDA Link 10/2014 - 01/2013
4	Carbonic Anhydrase IXIBA 05/2013 - 05/2010
4	Cell Cycle ProteinsIBA 08/2003 - 02/2002
3	Fos-Related Antigen-2IBA 06/2022 - 02/2008
3	PlatinumIBA 01/2022 - 01/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 04/2010
3	Protein Isoforms (Isoforms)IBA 01/2020 - 05/2003
3	Biological ProductsIBA 03/2018 - 09/2011
3	Peptide Hydrolases (Proteases)FDA Link 01/2017 - 07/2004
3	Progesterone Receptors (Progesterone Receptor)IBA 12/2014 - 02/2003
3	Estrogens (Estrogen)FDA Link 10/2014 - 02/2003
3	Plasminogen Activator Inhibitor 1IBA 01/2014 - 07/2004
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 07/2009 - 07/2004
3	Cyclin EIBA 04/2003 - 02/2002
2	SelectinsIBA 06/2022 - 11/2017
2	Angiogenesis InhibitorsIBA 01/2022 - 01/2013
2	Vascular Endothelial Growth Factor CIBA 01/2022 - 06/2017
2	E-SelectinIBA 01/2020 - 01/2013
2	kifunensineIBA 11/2019 - 01/2018
2	MannosidasesIBA 11/2019 - 01/2018
2	CEACAM1 ProteinIBA 01/2018 - 02/2002
2	Complementary DNA (cDNA)IBA 01/2017 - 01/2012
2	Hyaluronic Acid (Hyaluronan)IBA 01/2017 - 04/2016
2	Cadherins (E-Cadherin)IBA 01/2016 - 09/2015
2	LectinsIBA 06/2015 - 07/2007
2	Androgen Receptors (Androgen Receptor)IBA 12/2014 - 05/2013
2	Progesterone FDA LinkGeneric 10/2014 - 10/2014
2	Tamoxifen FDA LinkGeneric 05/2014 - 11/2008
2	ImmunosorbentsIBA 01/2014 - 01/2011
2	DNA (Deoxyribonucleic Acid)IBA 10/2011 - 11/2009
1	LigandsIBA 06/2022
1	P-SelectinIBA 06/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	SialyltransferasesIBA 11/2018
1	Glycoproteins (Glycoprotein)IBA 11/2018
1	alpha-Mannosidase (LAMAN)IBA 01/2018
1	IntegrinsIBA 11/2017
1	GlycosaminoglycansIBA 01/2017
1	Hyaluronan SynthasesIBA 01/2017
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2017
1	CalpainIBA 01/2016
1	osteoblast cadherinIBA 09/2015
1	plants leukoagglutininsIBA 06/2015
1	ChromatinIBA 12/2014
1	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 12/2014
1	GlycoconjugatesIBA 06/2014
1	Tyrosine (L-Tyrosine)FDA Link 05/2014
1	Estrogen Receptor alphaIBA 05/2014
1	Phosphotransferases (Kinase)IBA 05/2014
1	Plasminogen InactivatorsIBA 01/2014
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2014
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2014
1	Ubiquitin Thiolesterase (Ubiquitin Carboxy-Terminal Hydrolase)IBA 10/2013
1	AntibodiesIBA 05/2013
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2013
1	Blocking AntibodiesIBA 01/2013
1	Indicators and Reagents (Reagents)IBA 08/2012
1	TensinsIBA 08/2012
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 08/2012
1	Nucleic AcidsIBA 10/2011
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 08/2011
1	Carcinoembryonic AntigenIBA 02/2011
1	squamous cell carcinoma-related antigenIBA 01/2011
1	Trastuzumab (Herceptin)FDA Link 01/2011
1	human VEGFA proteinIBA 04/2010

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2006
5	Drug Therapy (Chemotherapy) 01/2022 - 01/2006
2	Radiotherapy 04/2016 - 04/2012
1	Subcutaneous Injections 06/2022
1	Adjuvant Chemotherapy 03/2018